TVRD Stock Alert: Why Atlantic Trading Called Tvardi Therapeutics on Phase 1 Trial Results

TVRD (Tvardi Therapeutics) caught our attention on the morning of July 7, 2026, after the company dropped a significant clinical catalyst before the opening bell. Before markets opened, Tvardi announced positive Phase 1 results for TTI-109, its next-generation oral small-molecule STAT3 inhibitor in development for inflammatory and proliferative diseases.

The data confirmed the drug’s prodrug design worked as intended, rapidly converting to its active form within two hours, while delivering pharmacodynamic evidence of real target engagement, with reductions of up to 60% in disease-relevant immune cell populations.

Crucially, it also showed meaningfully improved tolerability compared to its predecessor, with diarrhea episodes substantially shorter in duration. For a clinical-stage biotech, that kind of clean Phase 1 readout across safety, pharmacokinetics, and early efficacy signals is exactly the type of binary catalyst that moves share prices.

A Form 8-K was simultaneously filed with the SEC, formalising the disclosure and adding further visibility to the news across trading platforms.

From the open, TVRD held its uptrend and began gaining volatility (the kind of price action that follows a strong pre-market catalyst when momentum builds through the session). The stock was moving with purpose, and our team monitored it closely as the technical setup developed. We waited for our strategy to fully align before making a move.

Once our technical analysis gave us the confirmation we needed, we made a call to the Atlantic Trading community, alerting members to the opportunity in real time.